Scientists Discover Drug That Reverses Rare Blood Disorder by Boosting Protein Production
Researchers found that inhibiting LSD1 enzyme increases SEC23A protein levels, potentially treating congenital anemia.
Summary
Scientists discovered that blocking an enzyme called LSD1 can treat a rare inherited blood disorder called congenital dyserythropoietic anemia type II (CDAII). This condition prevents proper red blood cell formation due to mutations in the SEC23B gene. Researchers found that LSD1 inhibitors increase production of SEC23A, a related protein that can compensate for the faulty SEC23B. Testing in human cells and mouse models showed the treatment restored normal red blood cell development without harmful side effects. The drug RN1 successfully reversed the blood disorder by allowing cells to produce more of the compensatory protein, offering hope for patients with this currently untreatable condition.
Detailed Summary
Congenital dyserythropoietic anemia type II (CDAII) is a rare inherited blood disorder that impairs red blood cell formation, leading to chronic anemia and related health complications. This condition results from mutations in the SEC23B gene, which produces a protein essential for proper cellular function during red blood cell development.
Researchers at the University of Michigan conducted an innovative study using human cell lines and mouse models to identify potential treatments. They created cells that could track SEC23A protein levels and screened thousands of compounds to find ones that increased its production. SEC23A is nearly identical to SEC23B and can compensate for the defective protein when present in sufficient quantities.
The team discovered that inhibiting lysine-specific demethylase 1 (LSD1) dramatically increased SEC23A production. LSD1 normally suppresses SEC23A gene expression by binding to its promoter region. When researchers used the LSD1 inhibitor RN1, they observed restored red blood cell development in both human cells and CDAII mouse models, without interfering with normal cell growth or differentiation.
These findings represent a significant breakthrough for CDAII patients, who currently have limited treatment options beyond supportive care like blood transfusions. The research demonstrates how understanding gene regulation mechanisms can lead to targeted therapies that work around genetic defects rather than trying to fix them directly.
While promising, this research is still in early stages and requires clinical trials to establish safety and efficacy in humans. However, the approach of using existing drugs to modify gene expression offers a potentially faster path to treatment than developing entirely new medications.
Key Findings
- LSD1 inhibitor RN1 restored normal red blood cell formation in CDAII models
- Treatment increased SEC23A protein levels without affecting cell growth or development
- LSD1 directly suppresses SEC23A gene expression by binding to its promoter
- Genetic deletion of LSD1 achieved similar therapeutic effects as drug inhibition
- Mouse studies confirmed the treatment ameliorated CDAII symptoms
Methodology
Researchers used human erythroid cell lines with fluorescent protein tracking, screened small-molecule compounds, and validated findings in human stem cell-derived red blood cells and CDAII mouse models. The study employed both pharmacological inhibition and genetic deletion approaches to confirm LSD1's role.
Study Limitations
The study was conducted primarily in cell culture and mouse models, requiring human clinical trials to establish safety and efficacy. Long-term effects of LSD1 inhibition are unknown, and the treatment approach may not work for all CDAII patients depending on their specific genetic mutations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.